Are impulse control disorders the last Parkinson’s ‘taboo’?
PD in Practice
Author: Almaz OhenePublished: 27 July 2017
Prep: Cook: Serves:
The National Institute for Clinical Excellence (NICE) in the UK has just updated their guidelines on Parkinson’s disease, including additional material on impulse control disorders. Matt Eagles – who was diagnosed with young-onset Parkinson’s at just eight years old – opens up about how his wedding was almost cancelled due to his gambling impulses caused by dopamine agonist patches, how his neurologist and bank intervened, and how he hopes that these new guidelines will encourage others to speak out
In just a few weeks in the winter of 2013, Matt Eagles gambled away thousands of pounds that he and his fiancée had saved for their wedding, set for the following spring.
He wasn’t trying to sabotage his relationship; he was suffering from an impulse control disorder caused by his Parkinson’s medication. Some 18 months previously, he had started using a ‘dopamine agonist’ – a skin patch that slowly releases dopamine-like medication to stimulate the brain cells.
The patch had been working well and had allowed him to work as a sports photographer at the London 2012 Olympic Games. However, Matt believes that an emotional trauma, in which he and his partner suffered the loss of a baby girl, triggered a change in the way the medication worked for him.
He suddenly found himself engrossed in gambling apps on his phone.
Matt, who has lived with Parkinson’s for more than 40 years, recalls: “I’d go to the bathroom just to play on fruit machines, video poker and roulette in secret – losing the money that my fiancée and I had saved.”
But sometimes he would win the money back again.
“One day I was sitting with my fiancée in the lounge, secretly playing video poker. I won about seven thousands pounds in just one hand. I must have pumped my fist and shouted, “Get in!” or something, as my fiancée asked me what I was so pleased about.
“At that moment, I had to admit what I’d been doing and was so ashamed of myself. My fiancée said, ‘But this isn’t you Matt’. Since we’d both taken time to research the side effects of my Parkinson’s medications, we put two and two together and decided that I must be suffering from an impulse control disorder.
“I have a very good relationship with my specialist in London, and so when we called the clinic it took us just a week to get an appointment. I was still gambling during that week, but not nearly as much since everything was all out on the open.”
Matt Eagles shooting women’s rugby
The doctor decided to wean Matt from the medication and reduced the size of his patch over two to three weeks.
“As the days went by, I felt fewer impulses to gamble, which was such a relief.”
Although, by now, Matt had all but stopped gambling, he still had the issue of the lost wedding fund to contend with.
“My fiancée and I talked it out and many tears were shed. It was touch-and-go at times. Fortunately, she still wanted to get married but only on the proviso that I get the treatment that I needed, which, realistically, meant that I wouldn’t be able to go back on the dopamine agonists.
“The drugs really did help with mobility, so coming off them has meant that my Parkinson’s is worse. But it’s a consequence that I’ve learned to live with. The medication was literally ruining my life.”
In addition to helping control movement, balance and walking, dopamine also plays an important role in the part of the brain that controls reward and motivation.
Some Parkinson’s medications, particularly dopamine agonists – medications that act like dopamine to stimulate your brain cells – and, in some cases, levodopa – have been linked to impulsive and compulsive behaviour behavioural patterns.
Research has shown that around 17% of people with Parkinson’s who take dopamine agonists experience impulsive and compulsive behaviour, although it is not clear exactly how the medications cause the changes in behaviour.
Medications affect people in different ways, but research suggests that you may be more likely to experience impulsive and compulsive behaviour if you are:
– someone with a history of addictive behaviour
– someone who has a family history of gambling or alcohol abuse
– a younger person with Parkinson’s
– a single person who lives alone
Matt believes that people with Parkinson’s should be prepared to share their stories of impulse control disorders to help break the taboos surrounding them.
“I know so many people that have suffered severe consequences from dopamine agonists– people who haven’t told their specialists or families, but have admitted to having problems within in their private Parkinson’s communities.”
He also thinks that institutes such as banks need to be prepared to offer help.
“I was lucky in that my specialist was wrote a letter to my bank stating that it was the drugs that were making me reckless with my money, so the largest of my debts actually got written off.”
Matt and his wife have now been married for three years. He is not currently using dopamine agonist patches and no longer has gambling issues.
Matt Eagles telling a joke on his wedding day
You can read the new NICE guidelines on Parkinson’s disease in full here and the section on impulse control disorders here
“My voice matters”: the Parkinson’s caregiver raising awareness
Advocate Leslie Peters on the challenges faced by carers
7 days ago
New insights on immune cell process and Parkinson’s disease
Insoluble clumps of the protein alpha-synuclein, which can cause damage to brain cells, have been previously linked to Parkinson’s. Now, scientists in Germany, France and the US have uncovered new details on how brain cells respond to these clusters. The researchers discovered that the brain’s immune cells may be able to join together to break down the protein clumps. According to a press release, this was previously unknown. They also found that these neighbouring cells share mitochondria – structures that generate energy for chemical reactions – to help one another. In certain mutations associated with Parkinson’s, this process may be impaired. The researchers hope this insight could inform the development of new therapies. “We have opened the door to a field that will certainly engage researchers for many years to come,” said Professor Dr Michael Heneka, director of the Department of Neurodegenerative Diseases and Geriatric Psychiatry at the University Hospital…
Could analysing skin oil help diagnose Parkinson’s disease?
Parkinson’s disease patients tend to have high levels of oil, known as sebum, on their skin’s surface. Now, a study has suggested that analysing this substance may help when diagnosing the condition. The study revealed that sebum contains significant amounts of genetic material, specifically the molecule ribonucleic acid (RNA). Analysis of RNA contained in sebum – that is, skin surface lipids RNA, or SSL-RNA – could offer insights into a person’s health. Researchers in Japan examined SSL-RNA in men and women with and without Parkinson’s. The results suggested that the SSL-RNA profiles of those with Parkinson’s had “different characteristics” than those without. The researchers then tested whether examining these profiles with machine learning could reveal those who had Parkinson’s – and who didn’t. The team’s algorithm indicated a “relatively robust discriminatory ability,” supporting the further use of SSL-RNA as part of a future “non-invasive” method for diagnosis.
‘Sonic hedgehog’ protein could impact Parkinson’s disease dyskinesia
Dyskinesia is often caused by extended use of the common Parkinson’s medication levodopa – and can be debilitating for those with the condition. Now, researchers in the US may have found a way to suppress these involuntary movements through a protein called ‘sonic hedgehog’. To conduct their study, the team administered levodopa and sonic hedgehog agonists to rodent and non-human primate models of the condition. The results revealed that dopamine neurons use the protein to communicate with other neurons thought to play a role in levodopa-induced dyskinesia. Increased signalling of sonic hedgehog pathways was found to reduce this dyskinesia – providing “novel insight” into its formation and a “potential therapeutic solution”. “What we find,” wrote corresponding study author Professor Andreas Kottmann, “is that in several animal models, by replacing … dopamine together with agonists that mimic the effects of sonic hedgehog, these dyskinesias can be very much suppressed.”